beth israel deaconess medical center a harvard medical school teaching hospital

  • Contact BIDMC
  • Maps & Directions
  • Other Locations
  • Careers at BIDMC
  • Smaller Larger

Find a Doctor

Request an Appointment

Smaller Larger

Light Scattering Spectroscopy Helps Doctors Identify Early Pancreatic Cancer

New optical tool predicts malignant potential of cysts with 95 percent accuracy, compared to 58 percent accuracy with current test

• New light-scattering research tool offers minimally-invasive, highly accurate means of identifying pre-cancerous and cancerous pancreatic lesions.
• Currently, no diagnostic technique exists to reliably distinguish between pre-cancerous cysts from benign ones, leading either to unnecessary surgery or untreated malignancy.
• New technique requires further testing, but could represent a major advance against pancreatic cancer.

BOSTON – Pancreatic cancer has the lowest survival rate among all major cancers, largely because physicians lack diagnostic tools to detect the disease in its early, treatable stages. Now, a team of investigators led by Lev T. Perelman, PhD, Director of the Center for Advanced Biomedical Imaging and Photonics at Beth Israel Deaconess Medical Center (BIDMC), has developed a promising new tool capable of distinguishing between harmless pancreatic cysts and those with malignant potential with an overall accuracy of 95 percent. The team’s preliminary data was published online today in the journal Nature Biomedical Engineering.

The new device uses light scattering spectroscopy (LSS) to detect the structural changes that occur in cancerous or pre-cancerous cells by bouncing light off tissues and analyzing the reflected spectrum. The results could one day help guide physicians’ decision making when considering whether the presence of pancreatic cysts requires surgery, a high-risk procedure. Today, because of the lack of less-invasive diagnostic methods, more than half of these procedures turn out to have been unnecessary.

“About one-fifth of pancreatic cancers develop from cysts, but not all lesions are cancerous,” said Perelman, who is also Professor of Medicine and Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School. “Considering the high risk of pancreatic surgeries and the even higher mortality from untreated pancreatic cancers, there’s an obvious need for new diagnostic methods to accurately identify the pancreatic cysts that need surgical intervention and those that do not.”

In Perelman and colleagues’ series of experiments, the LSS technique achieved 95 percent accuracy for identifying malignancy. Cytology – the only pre-operative test currently availably – is accurate only 58 percent of the time. While the new technique requires further testing, LSS could represent a major advance against pancreatic cancer.

“This tool is a technology that is transformative in the evaluation of pancreatic cysts,” said co-lead author Douglas K. Pleskow, MD, Clinical Chief of the Division of Gastroenterology at BIDMC. “It provides a high level of precision in the detection of potential malignant transformation of these cysts.”

Pancreatic cysts are common, and today’s high-definition scanning technologies like MRI and CT imaging are detecting them with increasing frequency. Despite their high resolution, these scanners provide doctors with limited information about cysts’ malignant potential.

Currently, physicians rely on minimally-invasive fine needle aspiration (FNA) biopsies to test pancreatic cysts for malignancy. The biopsy removes fluid from the cysts, which is then analyzed for cancer cells and other telltale signs of the disease, a process called cytology. However, the test fails to detect cancer about half the time, leaving high-risk surgery as the current gold-standard means of diagnosing pancreatic cysts.

To test the accuracy of the LSS system, Perelman and colleagues collected and analyzed the reflected light from 13 cysts taken from recent surgeries. Next, they compared their findings with the results from pre-operative imaging, FNA biopsies and post-operative tissues analysis. In all cases, the LSS diagnosis agreed with the post-operative analysis.

In a second experiment, the LSS tool was tested in 14 patients with pancreatic cysts who were undergoing the standard FNA biopsy. Measuring less than half a millimeter in diameter, the miniature experimental LSS fiber-optic probe was inserted in the FNA needle. Physicians spent two minutes or less measuring optical spectra from the internal cyst surface before collecting fluid from the cysts as part of the traditional biopsy. Out of nine patients whose cysts had been definitely diagnosed as either cancerous or benign, all were correctly identified by LSS.

Currently a research tool not yet available for use in routine clinical practice, the researchers will next assess the LSS system’s accuracy by continuing to analyze post-operative tissues as they become available.

In addition to Perelman and Pleskow, the study authors include BIDMC investigators: co-corresponding author Le Qiu, PhD; lead author Lei Zhang, PhD; Vladimir Turzhitsky, PhD; Eric U. Yee, MD; Tyler M. Berzin, MD; Mandeep Sawhney, MD; Shweta Shinagare, MD; Edward Vitkin, PhD; Yuri Zakharov, PhD; Umar Khan; Fen Wang, MD; Jeffrey D. Goldsmith, MD; Ram Chuttani, MD; and Irving Itzkan, PhD; and Saveli Goldberg, PhD, of Massachusetts General Hospital.

This work was supported by the National Institutes of Health grants R01 EB003473 and R01 CA205431 and the National Science Foundation grants CBET-1402926 and CBET-1605116.

About Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.

BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, MetroWest Medical Center, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and the Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.

###